Table 1 Patient characteristics
| Â | Level | Conventional Radiotherapy | Hypofractionated Tomotherapy | p |
|---|---|---|---|---|
|  | N = 64 | N = 59 |  | |
Age, years: mean (sd) | Â | 57.8 (11.6) | 55.1 (11.5) | 0.198 |
Karnofsky Performance Status: mean (sd) | Â | 94.1 (8.4) | 94.7 (7.2) | 0.678 |
Body Mass Index kg/m2: mean (sd) | Â | 25.7 (4.2) | 26.0 (5.4) | 0.720 |
Smoker: N (%) | No | 46 (72) | 38 (64) | 0.493 |
Yes | 8 (12) | 12 (20) | Â | |
Ex-smoker | 10 (16) | 9 (15) | Â | |
Laterality: N (%) | Right | 31 (48) | 24 (41) | 0.402 |
Left | 32 (50) | 35 (59) | Â | |
Bilateral | 1 (2) | 0 (0) | Â | |
Grade: N (%) | 1 | 18 (30) | 16 (28) | 0.549 |
2 | 25 (42) | 29 (51) | Â | |
3 | 17 (28) | 12 (21) | Â | |
Stage: N (%) | I | 28 (44) | 25 (42) | 0.577 |
IIA | 31 (48) | 26 (44) | Â | |
IIB | 5 (8) | 8 (14) | Â | |
Tumor Size mm: mean (sd) | Â | 19.8 (11.0) | 20.3 (11.6) | 0.820 |
Nodal Status: N (%) | Negative | 48 (75) | 38 (64) | 0.279 |
Positive | 16 (25) | 21 (36) | Â | |
ER: N (%) | Negative | 8 (12) | 11 (19) | 0.489 |
Positive | 56 (88) | 48 (81) | Â | |
PR: N (%) | Negative | 18 (28) | 13 (22) | 0.569 |
Positive | 46 (72) | 46 (78) | Â | |
HER2 FISH-amplified: N (%) | No | 61 (95) | 47 (82) | 0.047 |
Yes | 3 (5) | 10 (18) | Â | |
Mastectomy: N (%) | No | 45 (70) | 33 (56) | 0.142 |
Yes | 19 (30) | 26 (44) | Â | |
Axillary Lymph Node Dissection: N (%) | No [=SN only] | 45 (70) | 30 (51) | 0.043 |
Yes | 19 (30) [9 after SN] | 29 (49) [13 after SN] | Â | |
Chemotherapy Schedule: N (%) | None planned | 38 (59) | 29 (49) | 0.499 |
Prior to RT | 7 (11) | 7 (12) | Â | |
Concomitant | 19 (30) | 23 (39) | Â | |
Hormone therapy: N (%) | No | 9 (14) | 8 (14) | 0.155 |
Tamoxifen | 26 (41) | 16 (27) | Â | |
Letrozole | 26 (41) | 26 (44) | Â | |
Goserelin(*) | 3 (5) | 9 (15) | Â | |
Trastuzumab: N (%) | No | 61 (95) | 49 (83) | 0.055 |
Yes | 3 (5) | 10 (17) | Â | |
Nodal Radiotherapy: N (%) | No | 48 (75) | 39 (66) | 0.376 |
Yes | 16 (25) | 20 (34) | Â |